MedImmune

WuXi AppTec opens first cGMP biologics facility in China

Monday, October 22, 2012 11:11 AM

WuXi AppTec, a pharmaceutical, biotechnology and medical device R&D outsourcing company, has opened a cGMP biologics facility in China.

More... »

MedImmune, WuXi AppTec form joint venture to develop novel biologic for Chinese market

Monday, September 10, 2012 10:31 AM

MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, an R&D outsourcing company, have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.

More... »

Y-Prime names Greef as senior business analyst

Thursday, August 30, 2012 02:53 PM

Y-Prime Technologies, an Malvern, Penn.-based eClinical products and life sciences consulting services company, has expanded its international operations in Europe and has named Jeanette Anne Greef as senior business analyst in the U.K. office.

More... »

MedImmune to close vaccines sites in California

Tuesday, July 17, 2012 02:55 PM

Gaithersburg, Md.-based MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, closing its Mountain View, Calif., and Santa Clara, Calif., sites and consolidating its infectious disease and vaccines R&D to other existing sites. The changes are expected to be completed in 2014.

More... »

Axerion, AZ collaborate on biologic treatment approach for Alzheimer's

Wednesday, May 2, 2012 10:06 AM

Axerion Therapeutics, a private Connecticut-based biotech, and MedImmune, the global biologics arm of AstraZeneca, have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.

More... »

AstraZeneca commits additional $100m to MedImmune

Tuesday, November 29, 2011 02:22 PM

AstraZeneca has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.

More... »

U-M Medical School, MedImmune ink 3 year research agreement

Wednesday, November 23, 2011 09:42 AM

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects. The three-year strategic collaboration will bring scientists from one of the nation’s top medical research institutions together with scientists from one of the world’s leading developers of biologic therapies. UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

More... »

The CenterWatch Monthly, November 2011

Tuesday, November 1, 2011 02:05 PM

CRAs see role evolving into quality, compliance, start-up

More... »

AgonOx, MedImmune partner to develop cancer therapies

Monday, October 31, 2011 11:57 AM

AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

More... »

Trizzino joins Immunovaccine as CEO

Monday, September 12, 2011 12:44 PM

Immunovaccine has named John J. Trizzino chief executive officer, effective October 1, 2011. Trizzino will also be appointed to the company's board of directors.

More... »